We are live on ! Find out more
ALLR

Allarity Therapeutics
ALLR

6 hedge funds and large institutions have $516K invested in Allarity Therapeutics in 2023 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,447% more capital invested

Capital invested by funds: $33.3K → $516K (+$482K)

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

200% more funds holding

Funds holding: 2 → 6 (+4)

15.04% more ownership

Funds ownership: 0.11% → 15.15% (+15%)

Holders
6
Holders Change
+4
Holders Change %
+200%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
1
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$768K
2
AC
Armistice Capital
New York
+$557K
3
Citadel Advisors
Citadel Advisors
Florida
+$56.4K
4
VF
Virtu Financial
New York
+$55.1K
5
TSS
Two Sigma Securities
New York
+$26.9K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$23.9K

ALLR Hedge Fund Activity: Q3 2023 in Review

6 of the 6,312 institutional investors tracked by Wall St. Rank reported a position in Allarity Therapeutics (ALLR) for Q3 2023, worth a combined $516K — up 1,447% from $33.3K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new ALLR positions and 1 closed out — a net gain of 4 holders — while 1 added to existing stakes and 0 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $768K. The largest seller was UBS Group, exiting entirely with an estimated $23.9K sold.

  • 6 institutional investors held Allarity Therapeutics (ALLR) as of Q3 2023, up from 2 in Q2 2023.
  • Funds reported $516K of Allarity Therapeutics stock for Q3 2023, up 1,447% quarter-over-quarter.
  • 5 funds opened new Allarity Therapeutics positions in Q3 2023 and 1 closed out, a net change of +4 holders.
  • The largest Allarity Therapeutics buyer in Q3 2023 was Sabby Management, an estimated $768K added.
  • The largest Allarity Therapeutics seller in Q3 2023 was UBS Group, an estimated $23.9K sold.

Based on aggregated 13F filings for Q3 2023.